BCM
ADMS

BlueCrest Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

BlueCrest Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-11,038
Closed -$285K – 1894
2018
Q2 		$285K Buy
+11,038
New +$306K 0.01% 1135

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BlueCrest Capital Management's ADMS Position: Q3 2018 in Review

BlueCrest Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q3 2018, closing a stake of 11,038 shares — an estimated $285K sold.

BlueCrest Capital Management first reported a position in ADMS in Q2 2018 and held it in 1 quarter. The position peaked at $285K in Q2 2018. 125 funds tracked by Wall St. Rank hold ADMS as of Q3 2018.

  • BlueCrest Capital Management reported no remaining Adamas Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 11,038 Adamas Pharmaceuticals shares in Q3 2018, an estimated $285K.
  • BlueCrest Capital Management first reported a position in Adamas Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Adamas Pharmaceuticals position peaked at $285K in Q2 2018.
  • 125 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2018.

Based on BlueCrest Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.